Journal of International Oncology››2018,Vol. 45››Issue (8): 535-538.doi:10.3760/cma.j.issn.1673-422X.2018.09.005
Previous ArticlesNext Articles
Li Chao, Chen Junhua, Wu Jing
Online:
2018-09-08Published:
2018-11-15Contact:
Li Chao E-mail:445596048@qq.comLi Chao, Chen Junhua, Wu Jing. Effects of Kanglaite injection combined with NP chemotherapy for immune status, inflammatory factors and quality of life of patients with advanced NSCLC[J]. Journal of International Oncology, 2018, 45(8): 535-538.
[1] 华玲, 韩克起. 非小细胞肺癌中西医结合治疗概况[J]. 四川中医, 2013, 31(3): 153155. [2] 周世繁. DCCIK细胞联合化疗对晚期非小细胞肺癌患者免疫功能的影响[J]. 海南医学院学报, 2017, 23(4): 510513. DOI: 10.13210/j.cnki.jhmu.20161216.005. [3] 唐翠萍, 吴阳, 周寒静, 等. 康莱特注射液联合紫杉醇对人乳腺癌细胞的化疗增效作用[J]. 重庆医学, 2016, 45(24): 33363339. DOI: 10.3969/j.issn.16718348.2016.24.008. [4] 连宝涛, 黄超原, 庄振杰, 等. 康莱特注射液联合放疗用于非小细胞肺癌的系统评价[J]. 中国药房, 2016, 27(12): 16341637. DOI: 10.6039/j.issn.10010408.2016.12.18. [5] Liu Y, Liu Y, Fan ZW, et al. Metaanalysis of the risks of hypertension and QTc prolongation in patients with advanced nonsmall cell lung cancer who were receiving vandetanib[J]. Eur J Clin Pharmacol, 2015, 71(5): 541547. DOI: 10.1007/s0022801518311. [6] 魏瑜, 杨媚, 张建清, 等. 含铂双药对比非铂单药二线治疗晚期非小细胞肺癌的系统评价[J]. 中华肿瘤防治杂志, 2015, 22(4): 293299. [7] Wang Y, Zhang C, Zhang S, et al. Kanglaite sensitizes colorectal cancer cells to Taxol via NFκΒ inhibition and connexin 43 upregulation[J]. Sci Rep, 2017, 7(1): 1280. DOI: 10.1038/s41598017014802. [8] 包三裕, 张洪. 康莱特注射液作用机理及临床应用研究[J]. 长春中医药大学学报, 2011, 27(1): 139140. DOI :10.13463/j.cnki.cczyy.2011.01.074. |
[1] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[2] | Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113. |
[3] | Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[4] | Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei.Current status of research on exosomes in malignancies[J]. Journal of International Oncology, 2023, 50(8): 484-488. |
[5] | He Guangsi, Wang Jun, Feng Mengmeng.Predictive value of inflammatory markers of peripheral blood cells on prognosis in the advanced non-small cell lung cancer with immune therapy[J]. Journal of International Oncology, 2023, 50(6): 321-327. |
[6] | Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347. |
[7] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[8] | Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163. |
[9] | Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[10] | Chen Yi, Han Liang, Cai Li.Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors[J]. Journal of International Oncology, 2022, 49(9): 521-525. |
[11] | Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie.Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer: a study based on real-world data[J]. Journal of International Oncology, 2022, 49(7): 408-415. |
[12] | Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281. |
[13] | Liu Yonghong, Xue Lingbo, Bai Yang, Jin Jian, Zang Chunxia, Zhang Bo, Li Jie.Predictive value of systemic inflammation response index before treatment for pathological complete response in patients with breast cancer undergoing neoadjuvant chemotherapy[J]. Journal of International Oncology, 2022, 49(4): 210-215. |
[14] | Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu.Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(3): 140-145. |
[15] | Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng.Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(11): 665-670. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||